Investigators sought compare the efficacy and safety of a chemo-free approach to TKI + chemotherapy in newly-diagnosed adult Ph+ ALL.

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

In the phase 3 COBRA trial, researchers sought to compare the efficacy of KRd to VRd in newly diagnosed multiple myeloma patients regardless of cytogenic risk or transplant eligibility.

Except for public health advocates (72% opposed), more than 60% of each speaker type supported approval. Patients and family members with drug experience had the highest support for approval (99%), 12 ...

Guidelines expanded to include self-collection for HPV testing and revised guidance for exiting cervical cancer screening ...

Investigators in the phase 3 BENEFIT study evaluated MRD negativity at 12 and 24 months in patients with newly diagnosed multiple myeloma (NDMM) transplant-ineligible (TI) patients.

In this analysis from the phase 3 S1826 study, researchers aimed to show the durability of the efficacy of nivolumab plus doxorubicin, vinblastine, and dacarbazine in classic Hodgkin lymphoma.

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

HealthDay News — Adjunct corticosteroids probably reduce short-term mortality in adults with severe pneumonia or acute respiratory distress syndrome (ARDS), according to a review published online ...